Identification of a 1,2,4,5-Tetraoxane Antimalarial Drug-Development Candidate

From a library of over 150 1,2,4,5‐tetraoxanes, the candidate RKA 182 was selected for preclinical development as an antimalarial agent.

Tuesday, 31 March 2020

From a library of over 150 1,2,4,5‐tetraoxanes, the candidate RKA 182 was selected for preclinical development as an antimalarial agent. RKA 182 has outstanding in vitro activity against resistant strains of P. falciparum and retains this level of activity against southeast asian isolates that failed artemisinin‐based combination therapy.

Related Articles